CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Adrenalinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05990933
NCT05990933N/ACompleted

Role of Adrenaline in the Inflammatory Response in People with Diabetes Mellitus Type 1, and Healthy Individuals

Cees Tack·interventional·Posted Aug 14, 2023·Updated Nov 21, 2024

In Brief

A clinical study evaluating Adrenaline for Inflammatory Response and 2 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The primary aim of the present study is to study the effect of adrenaline administration on inflammatory parameters (e.g. leukocyte phenotype, cytokines, inflammatory proteins). Secondary objectives consist of the effect of adrenaline on atherogenic parameters. * All participants will receive intravenous infusion of adrenaline for an hour * We will draw blood at 7 time points, not including screening * Participants will be asked to return for a total of 4 times Researchers will compare 2 groups, healthy individuals versus people with diabetes type 1 to see if the inflammatory reaction to adrenaline differs between these two groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesNetherlands
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedAug 14, 2023
Enrollment StartDec 3, 2023
Primary CompletionSep 3, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 2.9 years ago

Interventions

Adrenalinedrug

Adrenaline infusion at a rate of 0.04ug/kg/min for 1 hour administered intravenously.